WuXi PharmaTech's CFO Now Also Chief Investment Officer

WuXi PharmaTech (Cayman) Inc. has announced that Edward Hu will serve as the new Chief Investment Officer in addition to his current role as Chief Financial Officer.


Hu will be responsible for companywide investments, including strategic investments in new businesses, corporate venture capital investments, mergers and acquisitions, and joint ventures. He has served as the company's Chief Operating Officer since January 2008 and as Chief Financial Officer since February 2009. He spearheaded efforts to build many of the company's new businesses, including biologics, toxicology, genomics, and clinical trial services in China.


He led the acquisition and integration of AppTec, Abgent, and MedKey. He also created and has managed WuXi's joint ventures with MedImmune to co-develop an innovative biologics product in China, and with PRA to create a clinical CRO in China that meets the highest international standards.


Suggested Articles

Some of you might have already been aware of the news that Questex—with the aim to focus on event business—will shut down permanently all media brands in Asia…

Some advice for transitioning into an advisory role

Global risks are intensifying but the collective will to tackle them appears to be lacking. Check out this report for areas of concern